Hypothermic Oxygenated machine PErfusion for high‐risk liver grafts for transplantation: A systematic review and meta‐analysis

Charles W. G. Risbey,Charles Thomas,Anita Niu,Ken Liu,Michael Crawford,Carlo Pulitano
DOI: https://doi.org/10.1111/aor.14814
2024-06-24
Artificial Organs
Abstract:This systematic review an meta‐analysis demonstrates that Hypothermic Oxygenated machine PErfusion significantly reduces the rate of re‐transplantation, non‐anastomotic strictures, 12‐month graft loss, early allograft dysfunction and total biliary complications following liver transplantation when compared to the historical standard preservation technique, static cold storage. Background Hypothermic Oxygenated machine PErfusion (HOPE) can reduce ischemic reperfusion injury and improve outcomes for liver transplant recipients. However, the effect of HOPE on high‐risk extended criteria donor (ECD) and donation after circulatory death determination (DCDD) grafts is incomplete, despite the expectation that this cohort benefit maximally from HOPE. Accordingly, this paper aims to characterize the effect of HOPE on ECD and DCDD grafts. Methods This study includes all papers comparing HOPE to static cold storage for high‐risk ECD and DCDD grafts. Systematic searches of Medline, Embase, and Scopus were completed using the terms "HOPE" OR "hypothermic oxygenated machine perfusion" AND "liver transplantation". Data were extracted and analyzed using IBM SPSS to perform the meta‐analysis. Results A total of 2286 records were identified, with 10 meeting the inclusion criteria. Overall, the quality of evidence is heterogenous with many papers relying on retrospective controls. However, pooled analysis demonstrates HOPE to significantly reduce the rate of early allograft dysfunction, 12‐month graft failure, re‐transplantation, total biliary complications, and non‐anastomotic strictures for high‐risk grafts. Conclusions There is good evidence that HOPE improves outcomes following liver transplantation across a number of biochemical and clinical endpoints for high‐risk grafts. Of note, the reduction in biliary complications and re‐transplantation is particularly significant given the morbidity associated with these endpoints. However, further, high‐quality prospective trials with contemporary controls and clinically relevant primary endpoints are needed to better define the impact of HOPE for this cohort of grafts.
engineering, biomedical,transplantation
What problem does this paper attempt to address?